z-logo
open-access-imgOpen Access
TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion
Author(s) -
Samy Lamouille,
Erin C. Connolly,
James W. Smyth,
Rosemary J. Akhurst,
Rik Derynck
Publication year - 2012
Publication title -
journal of cell science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.384
H-Index - 278
eISSN - 1477-9137
pISSN - 0021-9533
DOI - 10.1242/jcs.095299
Subject(s) - epithelial–mesenchymal transition , mtorc2 , biology , cancer research , cell migration , metastasis , pi3k/akt/mtor pathway , microbiology and biotechnology , cancer cell , cell , transforming growth factor , cancer , signal transduction , mtorc1 , genetics
In cancer progression, carcinoma cells gain invasive behavior through a loss of epithelial characteristics and acquisition of mesenchymal properties, a process that can lead to epithelial-mesenchymal transition (EMT). TGF-β is a potent inducer of EMT, and increased TGF-β signaling in cancer cells is thought to drive cancer-associated EMT. Here, we examine the physiological requirement for mTOR complex 2 (mTORC2) in cells undergoing EMT. TGF-β rapidly induces mTORC2 kinase activity in cells undergoing EMT, and controls epithelial cell progression through EMT. By regulating EMT-associated cytoskeletal changes and gene expression, mTORC2 is required for cell migration and invasion. Furthermore, inactivation of mTORC2 prevents cancer cell dissemination in vivo. Our results suggest that the mTORC2 pathway is an essential downstream branch of TGF-β signaling, and represents a responsive target to inhibit EMT and prevent cancer cell invasion and metastasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom